Podcasts about hospital research institute

This podcast will discuss Care for Children and Youth with Cerebral Palsy (GMFCS levels III to V). This podcast was created by Juliette Eshleman a medical student at the University of Calgary with the help of Dr. Scott McLeod, a Clinical Associate Professor at the Cumming School of Medicine in the department of pediatrics, and a Child Health & Wellness Researcher for the Alberta Children's Hospital Research Institute.. This PedsCases podcast focuses on an overview of care for children and youth with cerebral palsy, with a specific focus on those who are within the Gross Motor Function Classification System (GMFCS) levels III to V

As parents, it's natural to want to protect our children from harm—but could we be shielding them too much? Today, Lara sits down with Dr. Mariana Brussoni, a renowned researcher and advocate for outdoor, risky play in childhood. Dr. Brussoni is the Director of the Human Early Learning Partnership, a Professor in the Faculty of Medicine at the University of British Columbia, and an Investigator at the British Columbia Children's Hospital Research Institute. Her groundbreaking work explores the vital role that outdoor play, particularly play that involves an element of risk, has on children's overall development. From fostering resilience and independence to supporting cognitive and emotional growth, risky play is a key ingredient in helping children develop into confident and capable adults. In today's episode, we dive into the topic of risky play, breaking down what it is, why it's so essential, and how parents can find that delicate balance between safety and allowing their children the freedom to explore. Dr. Brussoni shares insights on how outdoor play not only strengthens physical abilities but also enhances problem-solving skills, risk assessment, and emotional regulation in kids. If you've ever hesitated to let your child climb a tree or explore beyond your sight, this episode will provide the reassurance and evidence you need to embrace outdoor adventures with confidence. Tune in to discover how a little risk can lead to big rewards in your child's growth and development. You won't want to miss this eye-opening conversation with Dr. Mariana Brussoni! Learn more about Dr. Brussoni's work:  https://www.outsideplay.org/ Follow @outsideplayubc on instagram ------ Follow Parenting Ed-Ventures on Instagram ⁠⁠⁠⁠⁠@parentingedventurespod⁠⁠⁠⁠ Learn more about Tutor Teach ⁠⁠⁠⁠⁠⁠⁠https://tutorteach.ca/⁠⁠⁠⁠⁠⁠⁠ ------ Intro: app.pipio.ai with voice “Charlie Z.” Intro Music: “Bunny Swell” Sting Music: Purple Planet Music - Timelapse

Children are safer today than they have ever been in history, but is that a good thing? What skills and experiences are they losing out on if they're not exploring the world around them in a way that requires thought and risk?  Dr. Mariana Brussoni is here to share more about this exact phenomenon.  Dr. Brussoni is a Professor at the University of British Columbia, Director of the Human Early Learning Partnership, and Investigator at the British Columbia Children's Hospital Research Institute. She studies how to bring risky play back to children's lives. Her research focuses on understanding the effects of outdoor risky play on children and breaking down the barriers to children's access to these opportunities. Risky play does not necessarily mean dangerous play. Risky play is all about allowing children to experience the world without the ever watchful eyes of their parents. Providing opportunities for them to navigate challenges on their own, outside, with friends and grow into the adults they're becoming. In this episode, we discuss:  What differentiates risky and dangerous play. The developmental benefits of risky play. How to find the balance between risky and safe play. How to expose your children to risky play. Connect with Mariana: Outside Play-https://www.outsideplay.org/ Questions:  What is risky play and why is it important? Why is it disappearing from children's lives? How do we find the balance between risk and safety? How do we bring back risky play? Disclaimer: This podcast does not provide medical advice. The information on this podcast is for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment.  Learn more about your ad choices. Visit megaphone.fm/adchoices

BC Children's Hospital Foundation has announced that after a decade of collaborative research with infectious disease researchers, a first-in-the-world discovery has been made at BC Children's Hospital Research Institute. The new evidence indicates that acute lymphoblastic leukemia, the most common type of childhood cancer, could be preventable through early-life infection of a common virus. Guest: Dr. Gregor Reid - Investigator at the Michael Cuccione Childhood Cancer Research Program at BC Children's Hospital Learn more about your ad choices. Visit megaphone.fm/adchoices

OverviewIn this episode of asPERusual, host Anna Chudyk sits down with Carrie Costello, Annette Majnemer and Gillian Backlin from the CHILD-BRIGHT Network. Our discussion includes: * An overview of CHILD-BRIGHT, including its key activities and ways to get involved;* Different ways in which CHILD-BRIGHT is actively seeking to increase diversity within their network;* Practical considerations for engaging with youth and families in research - from initiating relationships to evaluating engagement work. * Tips for fostering authenticity, respect, and reciprocity, and creating environments where engagement can thrive. The CHILD-BRIGHT Network is a pan-Canadian patient-oriented research network based at the Research Institute of the McGill University Health Centre. Created in 2016, it works to create brighter futures for children and youth with brain-based developmental disabilities and their families. Funded by the Canadian Institutes of Health Research (CIHR) under Canada's Strategy for Patient-Oriented Research (SPOR) and 15 funding partners across the country, this national network includes 500 researchers, clinicians, decision-makers, youth, and parents. Meet our guestsCarrie Costello is the Implementation Support Coordinator for The Center for Implementation. She is a graduate of the University of Victoria BFA program and came into research after her middle child was diagnosed early in life with a profound intellectual disability and a seizure disorder. She has been a parent partner in research on over 15 projects and is the primary co-investigator on two of these research studies.  She specializes in facilitating conversations with children and youth.  Carrie is the parent liaison for the CHILD-BRIGHT Network and previously was the Patient Engagement Coordinator at the  Children's Hospital Research Institute of Manitoba. In 2023, she won the Frank Gavin Patient Engagement Leadership Award and the Made With Patients Rising Star award for her work. Carrie is also an award-winning playwright for young audiences and an avid puppeteerAnnette Majnemer, OT, PhD, FCAHS is an occupational therapist with doctoral training in the neurosciences. She is Professor at the School of Physical & Occupational Therapy, a Senior Scientist at the Research Institute - McGill University Health Centre (Montreal Children's Hospital), and a member of Montreal's Centre for Interdisciplinary Research in Rehabilitation. She is the nominated principal investigator of CHILD-BRIGHT, a CIHR SPOR Network with patient-oriented research focused on children with brain-based disabilities and their families. CHILD-BRIGHT's mission is to foster a movement for change: moving patients into research teams, moving research into improved practice and policy, and moving children and families forward towards brighter futures.Gillian Backlin is a member of the CHILD-BRIGHT Network's National Youth Advocate Council and serves on other panels and committees within CHILD-BRIGHT, where she uses her skills and draws from lived experience to contribute. Gillian has completed the technical writing certificate at the British Columbia Institute of Technology and currently works as a research assistant while pursuing her bachelor's degree in public health. She also manages an online platform called Spastic & Fantastic to share her life and raise awareness about the stigmas associated with labels, such as “disabled.” In her free time, she enjoys spending time with friends, family, and her dog. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit asperusual.substack.com

BUFFALO, NY- May 8, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 8, entitled, “The association between neighborhood deprivation and DNA methylation in an autopsy cohort.” Previous research has found that living in a disadvantaged neighborhood is associated with poor health outcomes. Living in disadvantaged neighborhoods may alter inflammation and immune response in the body, which could be reflected in epigenetic mechanisms such as DNA methylation (DNAm). In this new study, researchers Lindsay Pett, Zhenjiang Li, Sarina Abrishamcar, Kenyaita Hodge, Todd Everson, Grace Christensen, Marla Gearing, Michael S. Kobor, Chaini Konwar, Julia L. MacIsaac, Kristy Dever, Aliza P. Wingo, Allan Levey, James J. Lah, Thomas S. Wingo, and Anke Hüls from Emory University, University of British Columbia, BC Children's Hospital Research Institute, Centre for Molecular Medicine and Therapeutics, and Atlanta VA Medical Center used robust linear regression models to conduct an epigenome-wide association study examining the association between neighborhood deprivation (Area Deprivation Index; ADI), and DNAm in brain tissue from 159 donors enrolled in the Emory Goizueta Alzheimer's Disease Research Center (Georgia, USA). “We found one CpG site (cg26514961, gene PLXNC1) significantly associated with ADI after controlling for covariates and multiple testing (p-value=5.0e-8).” Effect modification by APOE ε4 was statistically significant for the top ten CpG sites from the EWAS of ADI, indicating that the observed associations between ADI and DNAm were mainly driven by donors who carried at least one APOE ε4 allele. Four of the top ten CpG sites showed a significant concordance between brain tissue and tissues that are easily accessible in living individuals (blood, buccal cells, saliva), including DNAm in cg26514961 (PLXNC1). This study identified one CpG site (cg26514961, PLXNC1 gene) that was significantly associated with neighborhood deprivation in brain tissue. PLXNC1 is related to immune response, which may be one biological pathway how neighborhood conditions affect health. “The concordance between brain and other tissues for our top CpG sites could make them potential candidates for biomarkers in living individuals.” DOI - https://doi.org/10.18632/aging.205764 Corresponding author - Anke Hüls - anke.huels@emory.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205764 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts About Aging-US Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer's diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Dr Benseler is the Director of the Alberta Children's Hospital Research Institute and a Professor in the Department Pediatrics, Cumming School of Medicine at the University of Calgary

Medical genetics may be able to help us better predict the risk of type 2 diabetes, and maybe even how to modify risk. Dr. William Gibson discusses his research in this area, as well as what he has learned from studying the genetics behind very unique forms of diabetes.Dr. Gibson is an Investigator at the BC Children's Hospital, a Senior Clinician Scientist at the Laboratory for Obesity Genetics and Indirect Calorimetry (LOGIC) at BC Children's Hospital Research Institute. In addition, he is a Professor in the Department of Medical Genetics, Faculty of Medicine at the University of British Columbia.

By studying the biological differences between people from different sexes, could we find ways to improve health outcomes for women and their children? Dr. Angela Devlin is trying to find out. From gestational diabetes to the role of folate in our pancreas, she has much to share about this work.Dr. Devlin  is a Professor in the Faculty of Medicine at the University of British Columbia, an Investigator at the BC Children's Hospital, Co-Director of the Women+ and Children's Health Research Graduate Program at the University of British Columbia, and Director of the Healthy Starts Research Theme at the BC Children's Hospital Research Institute.

Is your child part of the 6-8% of kids in the U.S. with a food allergy? Knowing the signs, triggers, and what to do if it happens will help you navigate food allergies with confidence.Dr. Stacie Jones joined us for Food Allergy Awareness Week to share vital insights on managing food allergies and the exciting research her team is conducting.Dr. Jones is the director of the food allergy program at Arkansas Children's Hospital Research Institute and a professor of pediatrics at the University of Arkansas for Medical Sciences.

In someone without diabetes, blood sugars are controlled by a hormone called insulin. Insulin lowers blood sugar levels, and is produced by cells in the pancreas called beta cells. If someone is at risk of developing diabetes, their beta cells can't produce enough insulin, which puts the beta cells under stress. The beta cells try to adapt, but if this fails, a vicious cycle begins. On this episode, host Krista Lamb speaks with Dr. Dan Luciani about beta cells and his lab's work to better understand them. Dr. Luciani is an investigator at the BC Children's Hospital Research Institute in Vancouver, and an associate professor in the Department of Faculty of Medicine at the University of British Columbia.

Parent-Child Brain Connection for Life.Dr Catherine Lebel is an Associate Professor of Radiology at the University of Calgary and a Canada Research Chair in Pediatric Imaging. She leads the Child Brain & Mental Health Program at the Alberta Children's Hospital Research Institute and is a member of the Hotchkiss Brain Institute.  Dr. Lebel received her PhD in Biomedical Engineering from the University of Alberta and completed postdoctoral training in Neurology and Pediatrics at the University of California, Los Angeles. Her research uses MRI to study how brain structure and function change with age in typical children and those with neurodevelopmental disorders, including fetal alcohol spectrum disorder and learning disabilities. She also examines how brain structure and function are related to cognitive, behavioural and environmental factors, including the prenatal environment. This is an important episode showing how prenatal exposure to alcohol changes the fetal brain and its connections to different parts of the brain. Parents/carers are the single most important neuroplasticity opportunity for healthy brain development in their children.Learn all about Parent-Child Connections in the Brain.The amygdala is a small structure that sort of looks like an almond. And it's deep in the brain. And we have one on each side, one in each hemisphere. And it's involved in a lot of different things. But of primary interest here and in a lot of studies is its role in emotion processing, particularly fear and anxiety. So the amygdala has been implicated in a lot of mental health problems and behaviour problems in children. And in this study,  we've looked at the amygdala in children and how it's related to prenatal depression in their mothers.   So prenatal depression, of course, is a stressful experience. And it can change things like stress hormones like cortisol glucocorticoids, and these affect the foetus as well as the mum.  And so that's likely one of the mechanisms via which this maternal stress can impact child's brain development. And so what we saw in this paper is that this stress in mums, prenatally, this anxiety specifically, was related to the way the amygdala was functioning with other parts of the brains in the kids. So we use a technique called functional connectivity, where we look at how different parts of the brain are sort of functioning together, or how their signals over time are correlated, and how they look similar. And so we saw that this anxiety related to this functional connectivity between the amygdala and some other areas of the brain. Their team saw connections were sort of in the post central area of the brain, this is the kind of top and a little bit back part of the brain. And it's involved in a variety of functions really. Among them are things like, like movement. So it's kind of interesting that it showed relationships with the amygdala as well. But one of the important reasons to look at this is because we know these kids are at heightened risk of having anxiety problems themselves later in life. So I think we believe that these brain changes are a potential mechanism. So the moms' anxiety and pregnancy affect the growing brain, which kind of might predispose these kids to anxiety difficulties themselves.Prenatal stress, in the form of either anxiety or depression, is affecting pretty similar parts of the child, an infant's brain, these specifically are emotion areas, the limbic system, we call it, which includes the amygdala, includes parts of the prefrontal cortex, and it includes connections between them.  The role of the partner influences the symptoms in the mum, but also how it can influence kid's brains. It is pretty well known that partner support or any kind of sociSupport the showLearn more at www.profselenabartlett.com

Beta cells play a big role in diabetes, and what we know about them continues to evolve. On this episode, host Krista Lamb speaks with Dr. Bruce Verchere about beta cells and his lab's work to better understand them. Dr. Verchere is the director of the BC Diabetes Research Network and a Scientist at the BC Children's Hospital Research Institute in Vancouver.

Join me in a conversation about how social determinants of health are critical conversation and considerations for improving hearing health care for individuals and families.  Dr. Matthew L. Bush is an otolaryngologist, neurotologist, and professor at the University of Kentucky.  He received his medical degree from the Marshall University Joan C. Edwards School of Medicine in Huntington, W.Va. He then completed an Otolaryngology research fellowship and a Neurotology and Cranial Base Surgery fellowship at The Ohio State University Medical Center and Nationwide Children's Hospital Research Institute in Columbus. Dr Bush has a personal history of growing up in rural West Virginia -- driving a passion and purpose to engage in clinical research focusing on healthcare disparities in  hearing healthcare. Dr. Bush has published multiple peer-reviewed papers and has received grants supported by the National Institutes of Health. His reasearch and clinical focus has moved the field forward in thinking outside of the “ear” and influencing positive change looking at the 5 domains of social determinants of health to improve access to care. In this episode, Dr. Bush challenges each of us to start with ourselves and ask the question “What Can We Do?”.  Dr. Bush challenges each of us to physically spend time in the community listening and learning.   You can listen to this episode wherever you access podcasts and at: www.3cdigitalmedianetwork.com/empowear-audiology-podcast    

In Canada, leading stem cell scientists are working hard to find ways to use these cells to improve the health of people living with type 1 diabetes. On this episode, host Krista Lamb speaks with Dr. Francis Lynn from the BC Children's Hospital Research Institute. Dr. Lynn is leading research projects using stem-cell-derived beta cells, as well as exploring ways to use CRISPR technology in this work. He is also the winner of the 2021 Early Career Researcher Partnership Award from Diabetes Canada.

In Canada, leading stem cell scientists are working hard to find ways to use these cells to improve the health of people living with type 1 diabetes. On this episode, host Krista Lamb speaks with Dr. Francis Lynn from the BC Children's Hospital Research Institute. Dr. Lynn is leading research projects using stem-cell-derived beta cells, as well as exploring ways to use CRISPR technology in this work. He is also the winner of the 2021 Early Career Researcher Partnership Award from Diabetes Canada.

Historically, type 2 diabetes has been seen as a condition that comes with age. However, that continues to change as people are diagnosed earlier and earlier. In the past 10 years, rates of type 2 diabetes in teenagers have doubled in Canada. Preventing the condition in adolescents has never been more important. Our guest this week is Dr. Jon McGavock who is a professor in the Department of Pediatrics and Child Health at the University of Manitoba and an researcher at the Children's Hospital Research Institute of Manitoba.

Join us for an informative discussion with Dr. Richard Frye, Director of Autism Research and Director of the Autism Multispecialty Clinic at Arkansas Children's Hospital Research Institute. There is increasing evidence that mitochondrial dysfunction is associated with autism spectrum disorder. Learn more about the latest research investigating the causes of this relationship, including the role of oxidative stress for these children. Topics include: The evidence for mitochondrial disease and dysfunction in autism spectrum disorder The importance of the oxidative stress in autism spectrum disorder and its impact on mitochondrial function The evidence for a subset of children with autism with acquired mitochondria dysfunction as a result of high levels of oxidative stress About The Speaker Dr. Richard Frye is the Director of Autism Research at Arkansas Children's Hospital Research Institute, Director of the Autism Multispecialty Clinic at Arkansas Children's Hospital and Associate Professor in Pediatrics at the University of Arkansas for Medical Sciences. He received his MD/PhD from Georgetown University in 1998. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. Dr. Frye is a national leader in autism research. He has authored over 100 peer-reviewed publications and book chapters, and serves on several editorial boards of prestigious scientific and medical journals. Over the past several years he has completed several clinical studies on children with autism spectrum disorder (ASD), including studies focusing on defining the clinical, behavioral, cognitive, genetic and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that address underlying physiological abnormalities in children with ASD, including open-labels on tetrahydrobiopterin, cobalamin and folinic acid and a recent double-blind placebo controlled trial on folinic acid. Future research efforts are focused on defining physiological endophenotypes of children with ASD and developing targeted treatments.

Beta cells are a big area of interest for researchers looking at ways to treat or prevent type 1 diabetes. Dr. Peter Thompson from the Children's Hospital Research Institute of Manitoba joins us on the show today to discuss his work studying beta cells to try and find new therapies.

Guest: Dr. Nicole Racine, clinical psychologist and post-doctoral research fellow at the University of Calgary and the Alberta Children's Hospital Research Institute

Join Associate Professor Melanie Noel as they discuss the one thing they want people challenged by pain to know about.Melanie Noel, PhD, RPsych is an Associate Professor of Clinical Psychology at the University of Calgary and a Full Member of the Alberta Children's Hospital Research Institute and the Hotchkiss Brain Institute. She directs the Alberta Children's Pain Research Lab within the Vi Riddell Pain & Rehabilitation Centre at the Alberta Children's Hospital in Canada. Dr. Noel's expertise is on children's memories for pain and co-occurring mental health issues and pediatric chronic pain. She published guiding conceptual models of children's pain memory development, co-occurring PTSD and chronic pain, and fear-avoidance. Season Two of One Thing is powered by the Australian Pain Society For more information on One Thing check out onething.painsci.org or search for @OneThing_Pain on Twitter and Instagram. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Tune in to episode 64 of 17 Minutes of Science as we talk with Dr. Deborah Kurrasch about her recent paper and why she enjoys working with zebrafish so much! Dr Deborah Kurrasch is a Professor in the Department of Medical Genetics at the University of Calgary and a Scientist in the Alberta Children's Hospital Research Institute and the Hotchkiss Brain Institute. Dr Kurrasch's research is focused on characterizing the genetic programs that govern hypothalamic development, and how exposure to environmental chemicals changes these programs, using zebrafish, mice and human brain organoids as model organisms. Her lab has also developed a novel drug screening platform to uncover therapies for children with refractory epilepsy. Her work is funded by the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Canadian Foundation for Innovation, among other Foundations. Dr Kurrasch received her PhD in Molecular Pharmacology from Purdue University and conducted two postdoctoral fellowships, one at the University of Texas – Southwestern Medical Center in Dallas and one at the University of California – San Francisco. Dr Kurrasch has received various awards for her scholarly work and supervision of graduate students, most recently receiving the ASTech Women in Innovation award, 2021.

Tune into our latest episode featuring Dr. Nicole Racine, clinical psychologist and post-doctoral research fellow at the University of Calgary and the Alberta Children's Hospital Research Institute. In this episode, Dr. Racine shares actionable insights on the global-wide mental health crisis youth and adolescents are facing during the pandemic. Dr. Racine discusses topics such as the reopening of schools across Canada, possible long-term impacts the pandemic could have on Youth mental health, and much more.

We recorded this episode earlier this year before schools reopened and prior to the Delta Variant. And judging by the current mental health studies of adolescents, I do believe we were right on track and our words ring true today. Pediatrician, Director of Center for Child Health, Behavior, and Development at Seattle Children's Hospital Research Institute, and child health expert, Dr. Dimitri Christakis joins Dr. Phil on the next "Phil In The Blanks" to discuss the long-term effects of the COVID-19 crisis on children's health, education, and emotional well-being, and strategies to help them rebuild. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of the Treebark Podcast, Julia is joined by Dr. Anna MacKinnon to discuss Perinatal Mood & Anxiety Disorders and COVID-19.Dr. Anna MacKinnon is a post-doctoral fellow at the Alberta Children's Hospital Research Institute, in the Departments of Psychology and Community Health Sciences at the University of Calgary. Her research focuses on social determinants of child health and development, risk and resilience for perinatal mental health, as well as intervention programs for psychological distress and parenting.Currently, Dr. MacKinnon is a part of the team at the Healthy Families Lab researching Pregnancy During The COVID-19 Pandemic.Check out the Pregnancy During The Pandemic study at https://www.pregnancyduringthepandemic.com/For more information check out The Healthy Families Lab on their website https://www.healthyfamilieslab.com/ To learn more about Julia's work check out her website https://www.treehousemedical.ca/ See acast.com/privacy for privacy and opt-out information.

Americans are currently buried under a staggering $1.7 trillion in student debt, and many see no way out. This is why the Debt Collective, a debtor's union, has organized the Biden Jubilee 100, a debt strike carried out by 100 people, one for each of Joe Biden's first 100 days in office. In the first segment of this week's “Marc Steiner Show,” we talk with Umme Hoque, Organizing Director of the Debt Collective, about the fight to cancel all student loan debt. Then, Marc is joined by Dr. Stephanie DeGooyer, a residential Burkhardt Fellow at UCLA and an incoming assistant professor of English at UNC-Chapel Hill, and Srinivas Murthy, M.D., a clinical care specialist in British Columbia and researcher at the BC Children's Hospital Research Institute, to discuss why the global response to COVID-19 pales in comparison to past, internationally coordinated efforts to eradicate polio and smallpox. Tune in for new episodes of The Marc Steiner Show every Friday on TRNN.

Maximillian Alvarez 12 minutes ago@Lisa @Dwayne I've gotta be in this damn board meeting at noon so could we get MSS up on Spreaker and then I can publish on the website as soon as I'm out?HED:The debt is too damn high! SUBHED: We talk with Umme Hoque of the Debt Collective about the push to cancel all student debt; then, we examine why we have failed to fight COVID-19 the way we fought polio or smallpox. WEBSITE/YT DESCRIPTION: Americans are currently buried under a staggering $1.7 trillion in student debt, and many see no way out. This is why the Debt Collective, a debtor's union, has organized the Biden Jubilee 100, a debt strike carried out by 100 people, one for each of Joe Biden's first 100 days in office. In the first segment of this week's “Marc Steiner Show,” we talk with Umme Hoque, Organizing Director of the Debt Collective, about the fight to cancel all student loan debt. Then, Marc is joined by Dr. Stephanie DeGooyer, a residential Burkhardt Fellow at UCLA and an incoming assistant professor of English at UNC-Chapel Hill, and Srinivas Murthy, M.D., a clinical care specialist in British Columbia and researcher at the BC Children's Hospital Research Institute, to discuss why the global response to COVID-19 pales in comparison to past, internationally coordinated efforts to eradicate polio and smallpox. Tune in for new episodes of The Marc Steiner Show every Friday on TRNN.

Welcome to another episode of The Words Matter Podcast.On this episode I'm speaking with pediatric pain scientist and psychologist Dr Melanie Noel.Melanie is an Associate Professor of Clinical Psychology at the University of Calgary, and a full member of the Alberta Children's Hospital Research Institute and the Hotchkiss Brain Institute.She teaches and supervises within the CPA-accredited Clinical Psychology Graduate Program in the Department of Psychology at the University of Calgary.And her behavioural research lab is based within the Vi Riddell Children's Pain and Rehabilitation Centre at Alberta Children's Hospital.Melanie completed her PhD in Clinical Psychology and Dalhousie University Canada, and held a Post-Doctoral Fellowship in Pediatric Pain Research at the Seattle Children's Research Institute. The overarching aim of her research is to understand and harness the influence of cognitive-behavioral factors, like pain memories, on children's pain trajectories using developmental frameworks. Her interests cover the areas of acute pain (such as painful medical procedures such as surgeries or vaccinations) and chronic pain in a variety of clinical and healthy populations.Her clinical interests include child clinical and pediatric psychology populations, with particular interest in the intersection between children's physical and mental health.So in this episode we talk about: public health messaging in relation to pain, in particular the influence of these messages on children. the nature and prevalence of paediatric chronic pain, and some of the key predictors for such pain states. diagnostic uncertainty for children with chronic pain and their parents. her research in the area of children's anxiety and pain memories as cognitive-affective mechanisms underlying trajectories of pediatric pain and future pain as adults. the  dynamic and dyadic relationship between a parent's mood and behavioural responses to a child's  chronic pain and how parents' protective responses (such as pain catastrophising) influence a child's pain experience. her strategies to reconstruct and re-frame a Childs pain experience to engender more positive behaviours and attitudes towards pain. At the end of the show you'll hear our surprise that Melanie and I share a common experience, with her having triplets and me being a triplet. So this was an absolutely fascinating talk, with someone really at the edge of knowledge in this crucial field. Melanie's sheer enthusiasm and passion  for her work is a joy to listen to as well as her compassion for the participants and patients that are involved in her work.On many instances the conversation is directed to the role of parents, rather than clinicians; but this episode has huge value for those without children, and significant value even if you never see children in your clinical work.If you seek to obtain an understanding of where your adult patient's pain beliefs, emotional responses and behaviours may originate from this podcast offers a real insight.Find Melanie on Twitter @MelanieNoel If you liked the podcast, you'll love the Words Matter online course in effective language and communication when managing back pain - ideal for all MSK therapists and students (discounts for students available)Follow Words Matter on:Instagram @Wordsmatter_education @TheWordsMatterPodcastTwitter @WordsClinicalFacebook Words Matter - Improving Clinical Communication★ Support this podcast on Patreon ★

In Episode 22 of Play it Forward, Lukas chats to the incredible Dr. Mariana Brussoni. Mariana is an Associate Professor in the Department of Pediatrics and the School of Population and Public Health at the University of British Columbia (UBC), and an investigator with the British Columbia Children’s Hospital Research Institute and the BC Injury Research & Prevention Unit. Mariana also conducts research on children’s outdoor and risky play, adult attitudes related to children’s risk taking and safety, and designing supportive outdoor play environments. She has published her research extensively and her work was featured in CBC’s the Nature of Things 2019 documentary, The Power of Play. Mariana’s immense knowledge on risk in play and her expression that caught Lukas’s attention, “safety doing harm”, meant they would both have plenty to talk about! Lukas and Mariana discuss injury prevention, the importance of risk, memorable childhoods, failure leading to innovation and resilience, well-being in children, the 17-second rule and a whole lot more! Also, be sure to search through the amazing resources on the below websites. Enjoy! https://brussonilab.ca/ https://www.outdoorplaycanada.ca/ https://www.psychologytoday.com/au/blog/freedom-learn/201404/risky-play-why-children-love-it-and-need-it

UBC's Dr Jan Dutz joins Dr Kerri Purdy for a fascinating deep dive into the intersecting worlds of Dermatology and Rheumatology in this latest episode of Dermalogues. Topics covered include the best approach to the undifferentiated autoimmune-rheumatology patient, best tips on how to interpret auto-antibodies, treating cutaneous calcinosis in a dermatomyositis patient, what to do with a positive ANA result in a patient with a low likelihood for an autoimmune disease and much more. Dermatolofy Resident questions in this episode come from Krystina Cleminson of Dalhousie University and Robert Bobotsis and Mathew Nicolas of the University of Toronto. Dr Jan Dutz is a Dermatolgist and Rheumatologist. He is a Professor and Head of the Department of Dermatology and Skin Science at the University of British Columbia. He is also a Senior Scientist with the British Columbia Children’s Hospital Research Institute. This podcast is a production of the Canadian Dermatology Association. Produced by David McGuffin and Explore Podcast Productions (davidrcmcguffin@gmail.com) Theme music is by Lee Rosevere

Increasing and maintaining vaccine coverage is an important way to prevent the spread of disease and keep communities healthy.  Efforts to reduce COVID-19 transmission, such as social distancing, led to fewer people seeking non-urgent medical care and receiving routine vaccinations.  Recent studies demonstrate that childhood vaccine uptake has decreased since the onset of COVID-19, leaving many children under or unvaccinated.  Ensuring routine vaccination services during the COVID-19 pandemic is an important way to prevent the spread of serious illness, hospitalizations, and further strain on the healthcare system.  This fall it will be vital for individuals to get vaccinated for the flu to reduce the overall burden of respiratory illness, protect vulnerable populations, and decrease the burden on the healthcare system. In this episode, our guests give the national and state-level perspective of what to expect this upcoming flu season, and why it’s so important to adhere to a vaccination schedule. Speakers: Nancy Messonnier, MD, Director of the Center for the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention Jose Romero, MD, Interim State Health Official, Arkansas Department of Health; Chair, Advisory Committee for Immunization Practices; Section Chief of Pediatric Infectious Disease, Arkansas Children’s Hospital Research Institute. Resources: Vaccination Guidance During a Pandemic (CDC) Why Routine Immunizations are a Must—Even During a Pandemic (ASTHO)

Today Ontario officials suggested we could be in this thing for up to 2 YEARS! Eric Chapman had a chance to speak with Guy Dumont, Professor at UBC's Department of Electrical and Computer Engineering Principal Investigator, BC Children's Hospital Research Institute.  

Taylor Morriseau is a PhD candidate studying the molecular mechanisms underlying youth-onset type 2 diabetes at the Children's Hospital Research Institute of Manitoba. Her work looks at the possibilit

Taylor Morriseau is a PhD candidate studying the molecular mechanisms underlying youth-onset type 2 diabetes at the Children’s Hospital Research Institute of Manitoba. Her work looks at the possibility that a traditional diet may prevent or delay type 2 diabetes in Indigenous youth. She is also a passionate advocate and role model for Indigenous youth.

Dr. Christine Doucette is a scientist who studies beta cell development to help people with diabetes. She is part of a team at the Children’s Hospital Research Institute of Manitoba that is looking at a surge in type 2 diabetes cases in children and youth in Northern Manitoba’s Indigenous communities. She discusses how her team in the lab collaborates with the physician scientists in the clinic to better understand what’s happening and to work towards solutions.

Dr. Christine Doucette is a scientist who studies beta cell development to help people with diabetes. She is part of a team at the Children's Hospital Research Institute of Manitoba that is looking at

Dr. Brandy Wicklow from the Children's Hospital Research Institute of Manitoba studies Type 2 diabetes in children and youth. Once considered a condition that develops as people age, in recent years t

Dr. Brandy Wicklow from the Children’s Hospital Research Institute of Manitoba studies Type 2 diabetes in children and youth. Once considered a condition that develops as people age, in recent years there has been an increase in type 2 diabetes diagnosis in children and youth – in particular in Indigenous populations. Researchers around the world are looking at ways to stem the tide of this growing epidemic, including researchers in Manitoba who are working closely with those affected to find solutions.

Dr. Jan Dutz speaks with JCMS Editor-in-chief Dr Kirk Barber about the article Dutz co-authored in the Nov/Dec 2019 edition of the Journal of Cutaneous Medicine and Surgery. The article focuses on how East Asians exposed to the urate-lowering drug allopurinol have a predilection for severe cutaneous drug reactions such as drug-induced hypersensitivity syndrome or drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome/toxic epidermal necrolysis. Dr Barber and Dr Dutz discuss why screening of patients of East Asian descent for the presence of HLA-B*58:01 prior to allopurinol initiation has been a Canadian missed opportunity. And what more can be done to encourage wider use of this inexpensive screening test.Dr. Jan Dutz is Professor and Head of the Department of Dermatology and Skin Science at UBC. He is also a Senior Scientist with the British Columbia Children's Hospital Research Institute.Theme music by Lee RosevereProduced by David McGuffin - Explore Podcast Productions 

Dr. Jan Dutz speaks with JCMS Editor-in-chief Dr Kirk Barber about the article Dutz co-authored in the Nov/Dec 2019 edition of the Journal of Cutaneous Medicine and Surgery. The article focuses on how East Asians exposed to the urate-lowering drug allopurinol have a predilection for severe cutaneous drug reactions such as drug-induced hypersensitivity syndrome or drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome/toxic epidermal necrolysis. Dr Barber and Dr Dutz discuss why screening of patients of East Asian descent for the presence of HLA-B*58:01 prior to allopurinol initiation has been a Canadian missed opportunity. And what more can be done to encourage wider use of this inexpensive screening test. Dr. Jan Dutz is Professor and Head of the Department of Dermatology and Skin Science at UBC. He is also a Senior Scientist with the British Columbia Children’s Hospital Research Institute. Theme music by Lee Rosevere Produced by David McGuffin - Explore Podcast Productions  

Our genetic codes makes up who we are. Or does it? Just because we have a certain gene, it doesn’t mean it will be active. The field of epigenetics has opened up our understanding on how genes may, or may not, be turned on. And this can have implications for our health. For this podcast I’m joined by Dr. Angela Devlin (Twitter: @AngelaMDevlin), an Associate Professor in the Department of Pediatrics at the University of British Columbia. She also co-leads the Origins of Child Health and Disease Research Group at BC Children’s Hospital Research Institute. Angela is a leader in nutrition, metabolism and epigenetic processes in pregnancy and early childhood to help bring better understanding of the development of diabetes and heart disease. During the interview, Angela provides an introduction to the fascinating field of epigenetics and how it relates to your nutrition and health. Don’t forget to subscribe to the show and check out my blog, Feel Healthy with Dr. Scott Lear, to learn about the latest science to keep you healthy.

Chapter 1

"Soren Gantt is an Associate Professor of Pediatrics and the Head of the Division of Infectious Diseases at the University of British Columbia, and Director of Clinical Research at the BC Children's Hospital Research Institute. He has a strong clinical interest in CMV, caring for congenitally-infected infants as well as pediatric transplant patients with CMV-related disease. Dr. Gantt established the first targeted congenital CMV screening program in Canada, and directs studies aimed determining the optimal strategies and diagnostic assays for newborn screening for CMV. His academic interests include a broad range of CMV topics, including the virologic determinants of transmission, immune correlates of protection against infection and reinfection, and the development of preventive CMV vaccines.   Guest: DR. Soren Gantt Director of Clinical Research at B.C. Children's Hospital

Two Quebec elementary schools are experimenting with supervised “rough play” zones in the schoolyard. Dr. Mariana Brussoni, Associate Professor for the Department of Pediatrics and School of Population & Public Health at UBC and Investigator at the BC Children's Hospital Research Institute joins the show.

“Be careful, not too high.”“I wish you would not do that.”“Time to do homework.”“You have to worry about people out there. ““Come on in we have to go to your next scheduled activity.”These are common phrases parents utter to their children in the world today.  And, as many of us know, this may be a departure from the past where we had lots of free time to explore and take risks while we were growing up.Dr. Mariana Brussoni is both my guest today and a developmental pediatrician focused on risky play and, believe it or not, how we don't do enough of it.She helps us understand that we need to let our kids explore more on their own, take a few risks along the way and learn their own limits. I think you will enjoy listening to someone challenge our current beliefs about what is good parenting. I know I did.  BioDr. Mariana Brussoni is a developmental psychologist and Associate Professor in the Department of Pediatrics and the School of Population and Public Health at the University of British Columbia. She is an investigator with the British Columbia Children's Hospital Research Institute and the British Columbia Injury Research & Prevention Unit. Dr. Brussoni investigates child injury prevention, parenting and children's risky play.Connect  https://brussonilab.ca  @mbrussoni

Jane Shearer is a PhD associate professor in the Faculty of Kinesiology and member of the Alberta Children's Hospital Research Institute in the Cumming School of Medicine.

This month, Agri Arkansas takes a closer look at Arkansas Garden Corps. An AmeriCorps program hosted by the Childhood Obesity Prevention Research Program at the Arkansas Children’s Hospital Research Institute in Little Rock; Arkansas Garden Corps programs and members reach all corners of the Natural State. Plus, we travel up Petit Jean Mountain to visit the Camp Mitchell Agricultural Project. Also, Chris Hiryak of Little Rock Urban Farming teaches us a little bit about microgreens. 

00:00 - Why are bachelor parties getting so expensive??? We got a text from a listener asking if he is a jerk for not wanting to spend 300 bucks on an all-day stag. That got us talking about all the extra costs of being in a wedding party... dresses / tuxedos / gifts / destination wedding / COSTS A LOT 34:06 - Diabetes & the Indigenous community -- Dr. Jonathan McGavock, Ph.D, based out of the Children's Hospital Research Institute of Manitoba -- his research program is focused on the prevention and management of Type 2 Diabetes in youth 51:50 - DR. SYRAS! This week, we chat with psychologist Dr. Syras Derksen about the psychology of GAMBLING. www.drsyras.com 68:09 - Remember the WINNIPEG THUNDER? Chris Watchorn does -- he is the owner and creator of Oak + Oar, a clothing store/brand at The Forks. Chris has created a limited set of Winnipeg Thunder t-shirts and hats, which will be released on Saturday, June 17th. www.oakandoar.com 80:01 - A group of supporters of the Parker Wetlands will be at the Parker Forest tomorrow, because they are hearing that bulldozers will be there to clear the trees. The developer, Gem Equities, says they will not be doing this tomorrow. We speak with the spokesperson of the supporters, Cal Dueck. 86:05 - Hal Anderson tees up his weekend shows

Ahead on Biotechnology Focus Radio : Bellus Health back in the game with a new therapeutic asset, BC Cancer Agency scientists make two breakthrough discoveries, and RepliCel Life Sciences gets by with a little help from its friends. We have this and more in store for you on this week’s show. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene.   Our first story this week takes us to CALGARY, AB where a team of Canadian physicians and researchers are believed to be the first in the world to have used gene therapy to treat a patient with Fabry disease, a rare inherited enzyme deficiency that can damage major organs and shorten lifespan. Specifically, people with the disease have a gene called GLA that doesn’t function as it should; as a result their bodies are unable to make the correct version of a particular enzyme that breaks down a fat called Gb3. A buildup of Gb3 can lead to problems in the kidneys, heart and brain. In their experimental trial, the researchers led by Dr. Aneal Khan, a Alberta Health Services medical geneticist and member of the Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary collected a quantity of a Fabry patient’s own blood stem cells then used a specially engineered virus to augment those cells with copies of the fully functional gene that is responsible for the enzyme. The altered stem cells were then transplanted back into the patient on Jan. 11, 2017. While Dr. Khan says it’s too soon to say whether this therapy will ultimately be a long-term treatment for the disease, based on the team’s success in animal trials, he is hopeful it will be a beneficial to patients Dr. Jeffrey Medin, a researcher with the Medical College of Wisconsin and the project’s principal investigator, adds that the trial is a major step forward in treating inherited genetic diseases in adults. The treatment, which has been approved by Health Canada for experimental purposes, is also believed to be the first trial in Canada to use a lentivirus in gene therapy. In this case, the specially modified virus was stripped of its disease-causing capability and augmented with a working copy of the gene that’s responsible for the missing enzyme. The project is being funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. The Queen Elizabeth II Health Sciences Centre in Halifax and the University Health Network in Toronto are also recruiting people with Fabry disease for the trial. In R&D news, a team of BC Cancer Agency scientists has made two exciting drug discoveries that could potentially allow for new approaches to target various cancers more specifically, through the exploitation of mutations found only in cancer cells and not normal cells. The first discovery, which has already led to a clinical trial, exploits the inability of BRCA1/2 deficient cancers to repair their own DNA. The second discovery is of a drug-like molecule that can alter the way cells translate genetic information into proteins. Both discoveries were made by Dr. Sam Aparicio, head of the Department of Breast and Molecular Oncology, and his research team at the BC Cancer Agency.The first success in this area is a discovery published in Nature Communications, where Dr. Aparicio’s team has discovered that the drug, CX-5461, originally developed for cancers of the blood and lymph system, can be repurposed as a drug treatment for breast cancer. Still early in its clinical development life cycle, CX-5461 has been shown through Dr. Aparicio’s latest work, to bind to the DNA of certain regions of the genome causing it to fold up and interrupt the DNA copying process. Thus, the compound is selectively active in tumours from patients with mutations in the BRCA1/2 gene, known to cause a strong familial predisposition to breast cancer, and account for approximately 15 per cent of the population with the disease. The study is currently in Phase 1 of a multi-centre clinical trial coordinated by Canadian Cancer Trials Group, which began in June of 2016. Phase two will accept even more patients to determine whether the activity found through preclinical studies is reflected in responses in patients. Both Dr. Aparicio and Dr. Karen Gelmon, senior scientist, medical oncologist and the clinical trial lead for the study add that if the trial is successful, they then hope to expand testing to other types of cancer in the near future. In addition to the CX-5461 findings, a second paper published in Nature Communications communicates the discovery of a different prototype drug, a compound called ‘T3’, engineered to alter the way that cells translate DNA, through splicing of RNA, into proteins. According to the researchers, this small, yet highly-potent drug-like molecule, currently in lab-testing, is being used to understand how different breast cancer cells might be susceptible to having RNA splicing interrupted. The drug molecule interferes with the molecular machinery that stiches gene sequences together to make fully functional proteins. Mutations in RNA splicing genes and defects in splicing have been found in diverse cancers, including breast cancer. The prototype drug molecules are allowing Dr. Aparicio and his team to seek out situations where cancer cells are uniquely susceptible to interference with RNA splicing. As alluded to, both drug development studies are currently centered in breast cancer treatment, but hope to expand to other types, including prostate and ovarian. Dr. Aparicio and his team’s work was supported with strategic funding from the BC Cancer Foundation. In Business new, two European firms are teaming up with Vancouver based regenerative medicine company, RepliCel Life Sciences Inc.to assist RepliCel in getting its commercial-grade RCI-02 dermal injector prototypes manufactured and tested. One of the partnering firms, AMI, is an Austrian manufacturer of medical technology based near the shores of Lake Constance, within easy reach of Germany and Switzerland. AMI develops, manufactures and distributes their medical products throughout the world. All of them are made according to the highest quality standards and enable doctors to take even better care of their patients. The second partner, Art of Technology (AoT), is based in Zurich Switzerland and is an independent contract developer specializing in the design, development and miniaturization of complex customer specific electronic devices and embedded systems for use in industrial, medical and space applications. The RCI-02 injector itself was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes. According to RepliCel president and CEO, Lee Buckler, it is the world’s first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising, and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or intramuscularly (muscle) via an array of needle configurations ranging from a single needle to a 16 needle configuration (4×4) on one head. Buckler adds that the execution of these agreements covers what RepliCel believes to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE mark in Europe. The company hopes to have the device ready for a CE mark application and in the hands of a licensing and commercial partner next year. Our next story takes us to the Maritime provinces where the Terry Fox Research Institute is investing $5-million in support of New Brunswick researchers and their colleagues at other cancer centres in Canada to study how new precision medicine tools could improve, and potentially save the lives of patients diagnosed with the incurable cancer of the blood and bone marrow, known as multiple myeloma. The initiative is known as the Multiple Myeloma Molecular Monitoring (M4) Study, and Dr. Tony Reiman, a medical oncologist and professor at the University of New Brunswick, will lead the team, which comprises researchers and clinicians at multiple sites including Vancouver, Calgary, Toronto and Montreal. Dr. Reiman says that he hopes the five-year study will result in game-changing new approaches to identifying, treating and monitoring the disease in patients, including those who are at high risk of relapse. His team in Saint John will organize all the participating centres as well as conduct its own research and receive and bank specimens (blood and marrow) from the 250 myeloma patients that will participate in the project. Additionally, M4 study team members will use tests based on advanced techniques like immunoglobulin gene sequencing, multiparameter flow cytometry, PET scans, circulating tumour DNA analysis, and novel drug resistance assays to evaluate the patient specimens and other biosamples. Principal investigators at the partner sites are: Drs. Donna Reece and Suzanne Trudel, Princess Margaret Cancer Centre; Dr. Nizar Bahlis, University of Calgary; and Dr. François Bénard, BC Cancer Agency. Patients will be recruited by the study investigators at their own sites. Principal investigators Drs. Reece and Trudel (PM) explain their role in M4 study in the following audio. BrainStorm Cell Therapeutics Inc., a HACKENSACK, N.J.- based company developing adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM in the hopes of furthering its market authorization request for NurOwn®.  For our new listeners, CCRM is a Toronto-based company focused on developing and commercializing regenerative medicine technologies, specifically cell and gene therapies. Through the agreement, CCRM will help Brainstorm explore opportunities to access Health Canada’s early access pathway for treatment of patients with Amyotrophic Lateral Sclerosis (ALS).  If NurOwn® qualifies for Health Canada’s “Notice of Compliance with Conditions” pathway, it could be authorized in Canada for distribution in early 2018. Through the agreement, the company will work Patrick Bedford, manager of clinical translation and regulatory affairs at CCRM. Stacey Johnson (@msstaceyerin) , director, communications and marketing at CCRM and editor of Signals Blog discussed this deal recently via her regular Right Turn column Be sure to check it out at http://www.signalsblog.ca/right-turn-new-stem-cell-product-for-als-seeking-approval-in-canada/. For our final story, nearly a year since it’s failed KIACTA™ Phase 3 trial and subsequently being forced into pulling the plug on its KIACTA program, BELLUS Health is back from the brink as the Montreal-based company announced a new partnership and licensing deal with The NEOMED Institute to take over the development and commercialization activities for a potential new treatment for chronic cough. According to Bellus stakeholders,, this is a transformative transaction as this exclusive worldwide license agreement adds to the company’s pipeline a potentially best-in-class drug candidate, BLU-5937, an asset which was formerly known as NEO5937.  Its development through  the P2X3 antagonist program was initiated by AstraZeneca scientists in Montreal, and assigned to NEOMED in October 2012 when the NEOMED Institute was first launched. It was selected as a drug candidate to advance towards the clinic based on development efforts and extensive pre-clinical work in chronic cough done at NEOMED. According to Roberto Bellini, president and CEO of the company, the drug now going by its new name BLU-5937  will be a core focus of BELLUS’s drug development efforts. About the condition, Chronic cough is a cough that lasts eight weeks or longer and significantly impacts quality of life, with significant social (exclusion, embarrassment, difficulty speaking), physical (sleep deprivation, rib fracture, vomiting) and psychosocial (anxiety, depression) repercussions. It is estimated that in the U.S. alone, more than 2.7 million patients suffer from chronic cough that is not controlled by currently available medications. How BLU-5937 works to treat it, is it acts on a clinically validated target in the chronic cough pathway, the P2X3 receptor. Both the company and NEOMED believe BLU-5937 has the potential to become a best-in-class treatment option because of its superior potency and selectivity for the P2X3 receptor. These properties suggest BLU-5937 will be effective and less likely to cause a problematic side effect seen with less-selective drugs: taste disturbances that are significant enough to affect drug compliance. Under the terms of the agreement, BELLUS Health will pay NEOMED an upfront fee of $3.2 million, consisting of $1.7 million in cash with $1.5 million worth of BELLUS Health common shares (Approximately 5,802,177 shares). NEOMED will also be entitled to receive a royalty on net sales-based revenues. Additionally, in lieu of milestone payments, a certain portion of all other revenues received by BELLUS Health from BLU-5937 will be shared with NEOMED according to a pre-established schedule whereby the shared revenue portion decreases as the program progresses in development. Well that wraps up another episode of the Biotechnology Focus Podcast. We hope you enjoyed it. Be sure to let us know what you think, and we’re also always looking for story ideas and suggestions for future shows, and of course we’d love to hear from you as well, simply reach out to us via twitter @biotechfocus, or by email at the following email address  press@promotivemedia.ca. And remember, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca . For all of us here at Biotechnology Focus, thanks for listening

Interview with Dr. Celia Rodd, Associate Professor of Pediatric Endocrinology at the University of Manitoba. She is also clinician-scientist and epidemiologist at the Children’s Hospital Research Institute of Manitoba. In their cross-sectional study, Dr. Rodd and her co-author Dr. Atul Sharma found that the prevalence of overweight and obesity among Canadian children decreased from 30.7% to 27.0% between 2004 and 2013, following a period of dramatic growth during 1978–2004. Full research article (open access): www.cmaj.ca/lookup/doi/10.1503/cmaj.150854 ----------------------------------- Subscribe to CMAJ Podcasts on iTunes, Stitcher, Overcast, Instacast, or your favourite aggregator. You can also follow us directly on our SoundCloud page. Our podcasts are also released on www.cmaj.ca and on www.cmajblogs.com.